Diagnosis and disease modifying treatments in multiple sclerosis

Postgraduate Medical Journal

Volumn 81, Issue 959, 2005, Pages 556-561

  Zajicek, J ^a  

^a Clinical Neurology Research   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; AZATHIOPRINE; BETA INTERFERON; BETA1A INTERFERON; GLATIRAMER; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; LENERCEPT; MITOXANTRONE; NATALIZUMAB; PLACEBO; SALAZOSULFAPYRIDINE; SELEGILINE; TUMOR NECROSIS FACTOR ALPHA;

COCHRANE LIBRARY; DISEASE COURSE; HUMAN; MONOZYGOTIC TWINS; MULTIPLE SCLEROSIS; NEUROLOGIC EXAMINATION; NEUROPROTECTION; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSON DISEASE; PREVALENCE; RELAPSE; REVIEW; SYSTEMATIC REVIEW; THYROTOXICOSIS; TWIN CONCORDANCE; UNITED KINGDOM;

ADJUVANTS, IMMUNOLOGIC; DIAGNOSIS, DIFFERENTIAL; HUMANS; INTERFERON-BETA; MULTIPLE SCLEROSIS; PEPTIDES; RISK ASSESSMENT;

EID: 24744442748     PISSN: 00325473     EISSN: None     Source Type: Journal    
DOI: 10.1136/pgmj.2004.031294     Document Type: Review

References (34)

1. Fox CM, Bensa S, Bray I, et al. The epidemiology of multiple sclerosis in Devon: a comparison of the new and old classification criteria. J Neurol Neurosurg Psychiatry 2004;75:56-60.
2. Willer CJ, Dyment DA, Risch NJ, et al. Twin concordance and sibling recurrence rates in multiple sclerosis. Proc Natl Acad Sci USA 2003;100:12877-82.
3. Mumford G, Wood NW, Kellar-wood H, et al. The British Isles survey of multiple sclerosis in twins. Neurology 1994;44:11-15.
4. Sawcer S, Maranian M, Setakis E, et al. A whole genome screen for linkage disequilibrium in multiple sclerosis confirms disease associations with regions previously linked to susceptibility. Brain 2002;125:1337-47.
5. Compston DAS. Distribution of multiple sclerosis. In: Compston A, Lassmann H, McDonald I, et al, eds. McAlpine's multiple sclerosis. 3rd ed. London: Churchill Livingstone, 1998:63-94.
6. Charcot JM. Lecons sur les maladies du systeme nerveux faites a la Salpetriere. Vol 1. 4th ed. Paris: 1880.
7. Trapp BD, Peterson J, Ransohoff RM, et al. Axonal transection in the lesion of multiple sclerosis. N Engl J Med 1998;338:278-85.
8. Lucchinetti C, Bruck W, Parisi J, et al. A quantitative analysis of oligodendrocytes in multiple sclerosis lesions. A study of 113 cases. Brain 1999;122:2279-95.
9. Barnett MH, Prineas JW. Relapsing and remitting multiple sclerosis: pathology of the newly forming lesion. Ann Neurol 2004;55:458-68.
10. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis. Ann Neurol 2001;50:121-7.
11. Tintore M, Rovira A, Martinez MJ, et al. Isolated demyelinating syndrome: comparison of different MR imaging criteria to predict conversion to clinically definite multiple sclerosis. Am J Neuroradiol 2000;21:702-6.
12. Brex PA, Ciccarelli O, O'Riordan JI, et al. A longitudinal study of abnormalities on MRI and disability in multiple sclerosis. N Engl J Med 2002;346:158-64.
13. NICE. Full guidance on the use of beta-interferon and glatiramer for the treatment of multiple sclerosis. London: NICE, 2002: 32. http:// www.nice.org.uk/page.aspx?o = 27635.
14. Duquette P, Girard M, Despault L, et al. Interferon beta-1b is effective in relapsing-remitting multiple- sclerosis - clinical-results of a multicenter, randomized, double- blind, placebo-controlled trial. Neurology 1993;43:655-61.
15. Duquette P, Despault L, Knobler RL, et al. Interferon beta-1b in the treatment of multiple sclerosis: Final outcome of the randomized controlled trial. Neurology 1995;45:1277-85.
16. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 1996;39:285-94.
17. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon beta-la in relapsing/remitting multiple sclerosis. Lancet 1998;352:1498-504.
18. Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 1995;45:1268-76.
19. European Study Group. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. European Study Group on interferon beta-1b in secondary progressive MS. Lancet 1998;352:1491-7.
20. Rice G, Incorarvaia B, Munari L, et al. Interferon in relapsing-remitting multiple sclerosis. Cochrane Library. Issue 4. Oxford: Update Software, 2001.
21. Munari L, Lovati R, Boiko A. Therapy with glatiramer acetate for multiple sclerosis. Cochrane Library. Chichester: Wiley, 2004.
22. Noseworthy JH, O'Brien P, Erickson BJ, et al. The Mayo Clinic-Canadian cooperative trial of sulfasalazine in active multiple sclerosis. Neurology 1998;51:1342-52.
23. Association of British Neurologists. Guidelines for the use of beta interferons and glatiramer acetate in multiple sclerosis. London: ABN, 2001. http:// www.theabn.org/downloads/msdoc.pdf.
24. Jacobs L, Beck R, Simon J, et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. N Engl J Med 2001;343:898-904.
25. Comi G, Filippi M, Barkhof F, and the Early Treatment of Multiple Sclerosis Study Group. Effect of early IFN treatment on conversion to definite MS: a randomised study. Lancet 2001;357:1576-82.
26. Sudlow CLM, Counsell CE. Problems with the UK government's risk sharing scheme for assessing drugs for multiple sclerosis. BMJ 2003;326:388-92.
27. Coles AJ, Wing M, Smith S, et al. Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis. Lancet 1999;354:1691-5.
28. Miller DH, Khan OA, Sheremata WA, et al. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2003;348:15-23.
29. Hohlfeld R. Biotecnnological agents for the immunotherapy of multiple sclerosis. Principles, problems and perspectives. Brain 1997;120:865-916.
30. Selmaj K, Raine CS. Tumour necrosis factor mediates myelin and oligodendrocyte damage in vitro. Ann Neurol 1988;23:339-46.
31. Zajicek J, Wing M, Scolding NJ, et al. Interactions between oligodendrocytes and microglia, a major role for complement and tumour necrosis factor in oligodendrocyte adherence and killing. Brain 1992;115:1611-31.
32. Lenercept Multiple Sclerosis Study Group. TNF neutralization in MS; results of a randomized, placebo controlled multicentre study. Neurology 1999;53:457-65.
33. Zajicek J, Fox P, Sanders H, et al. The use of cannabinoids for the treatment of spasticity and other symptoms related to multiple sclerosis-results of a multicentre randomised placebo-controlled trial (the CAMS study). Lancet 2003;362:1517-26.
34. Stocchi F, Olanow CW. Neuroprotection in Parkinson's disease: clinical trials. Ann Neurol 2003;53(suppl 3):S87-97, S97-9.